Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | PNP | P00491 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL766733 | 0.91 | POLA1 (0.62) | POLA1KDM4EPNPLMNATP53 | |
| SCHEMBL766453 | 0.91 | POLA1 (0.62) | POLA1KDM4EPNPLMNATP53 | |
| SCHEMBL30013461 | 0.91 | POLA1 (0.62) | POLA1KDM4EPNPLMNATP53 | |
| SCHEMBL23648150 | 0.89 | POLA1 (0.68) | POLA1KDM4EPNPLMNATP53 | |
| SCHEMBL5982591 | 0.89 | POLA1 (0.68) | POLA1KDM4EPNPLMNATP53 | |
| SCHEMBL3489507 | 0.89 | POLA1 (0.68) | POLA1KDM4EPNPLMNATP53 | |
| SCHEMBL8541032 | 0.89 | POLA1 (0.68) | POLA1KDM4EPNPLMNATP53 | |
| SCHEMBL3489505 | 0.89 | POLA1 (0.68) | POLA1KDM4EPNPLMNATP53 | |
| SCHEMBL14732688 | 0.89 | POLA1 (0.63) | POLA1KDM4EPNPLMNATP53 | |
| SCHEMBL22984019 | 0.89 | POLA1 (0.63) | POLA1KDM4EPNPLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6864049-B1 | Method for producing hybridization complexes whose stability is substantially independent of the base composition of two hybridized nucleic acid molecules | APPLIGENE-ONCOR S.A. (FR) | 2005-03-08 | — | — | US | claimed |
| JP-2000512843-A | — | — | 2000-10-03 | — | — | JP | claimed |
| EP-0954610-A1 | METHOD FOR PRODUCING HYBRIDISATION COMPLEXES WHOSE STABILITY IS SUBSTANTIALLY INDEPENDENT OF THE BASE COMPOSITION OF TWO HYBRIDISED NUCLEIC ACID MOLECULES | Appligene-Oncor S.A. (FR) | 1999-11-10 | — | — | EP | claimed |
| WO-1997049833-A1 | METHOD FOR PRODUCING HYBRIDISATION COMPLEXES WHOSE STABILITY IS SUBSTANTIALLY INDEPENDENT OF THE BASE COMPOSITION OF TWO HYBRIDISED NUCLEIC ACID MOLECULES | APPLIGENE-ONCOR S.A. (FR) | 1997-12-31 | — | — | WO | claimed |
| US-6864049-B1 | Method for producing hybridization complexes whose stability is substantially independent of the base composition of two hybridized nucleic acid molecules | APPLIGENE-ONCOR S.A. (FR) | 2005-03-08 | — | — | US | disclosed |
| EP-0954610-A1 | METHOD FOR PRODUCING HYBRIDISATION COMPLEXES WHOSE STABILITY IS SUBSTANTIALLY INDEPENDENT OF THE BASE COMPOSITION OF TWO HYBRIDISED NUCLEIC ACID MOLECULES | Appligene-Oncor S.A. (FR) | 1999-11-10 | — | — | EP | disclosed |
| WO-1997049833-A1 | METHOD FOR PRODUCING HYBRIDISATION COMPLEXES WHOSE STABILITY IS SUBSTANTIALLY INDEPENDENT OF THE BASE COMPOSITION OF TWO HYBRIDISED NUCLEIC ACID MOLECULES | APPLIGENE-ONCOR S.A. (FR) | 1997-12-31 | — | — | WO | disclosed |